

Pidotimod enters its first market

Italy became the first market for the anti-infective immunostimulant, pidotimod, on Mar 1. It was launched as Polimod® by Poli Industria Chimica, but is also being comarketed by Fidia as Pigitil®, by Max Pharma as Onaka®, and by Boehringer Mannheim as Axil®.

Pidotimod is approved for the treatment of patients with documented cell-mediated immunodepression during infections of the respiratory and urinary tracts. It affects the cell-mediated immune system by activating T lymphocytes, through interleukin 2 stimulation, and macrophages via activation of superoxide dismutase and chemotaxis.

Sachets and oral vial formulations are currently on the market, but intramuscular and tablet formulations have also been approved.

800187458